Jun 26 |
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
|
Jun 20 |
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
|
Jun 5 |
Psychedelic stocks fall as FDA panel rejects MDMA therapy
|
Jun 4 |
FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD (updated)
|
May 31 |
Psychedelic stocks mixed as FDA comments on MDMA therapy
|
May 31 |
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
|
May 27 |
ATAI: Enormous Potential Upside But No Clarity Yet
|
May 23 |
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
|
May 15 |
ATAI Life Sciences GAAP EPS of -$0.17 beats by $0.01
|
May 15 |
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
|